can semaglutide cause heart palpitations GLP-1 Weight Loss & AFib Risk: Safety Guide Wegovy and Heart Palpitations: Is

Only reconstitute individual vials as needed

Novo Nordisk and the Next Wave of Weight Loss Drugs The Two-Company Market: Q1 2026 Head to Head Key Numbers Total Revenue: $19.8B (+56% YoY) Adjusted EPS: $8.55 (+156%) Mounjaro: $8.66B (+100%+ YoY) Zepbound: $4.16B (+80% YoY) US Market Share: 60.1% 2026 Guide: $82-85B (raised $2B) Total Revenue: $10.8B (beat estimates) Adjusted EPS: $1.03 (beat) Wegovy: DKK 18.2B (+12% YoY) Wegovy Pill: $354M (doubled estimates) US Market Share: 39.4% 2026 Guide: Adjusted sales decline 4-12% at CER The GLP-1 market in 2026 is a two-company duopoly with a widening gap

The following individuals require detailed medical evaluation before IV Glutathione therapy can be considered, and certain contraindications may result in deferral or modification: Pregnancy & Breastfeeding Phase Ongoing Skin or Body Infections Immune System Sensitivities Uncontrolled Sugar Levels Slow Recovery or Repair Conditions A detailed skin, wellness, and medical assessment is conducted before recommending Glutathione IV Drip Treatment in Mumbai

C.et al (2015a)